National Institute for Health and Care Excellence

Draft for consultation

Lung cancer: diagnosis and management (update)

NICE guideline: acknowledgments

NICE guideline xxxx Authors and contributors September 2018

Draft for Consultation

Commissioned by the National Institute for Health and Care Excellence

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their careful or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright © NICE [2018]. All rights reserved. Subject to Notice of rights.

Contents

1

Guid	uideline developers		
1.1	Members of the NICE guideline committee	. 5	
1.2	Members of the Guideline Updates Team:	. 5	
1.3	Acknowledgements	. 5	

1 Guideline developers

1.1 Members of the NICE guideline committee

Name	Role
Gary McVeigh	Consultant Physician, Belfast (Guideline Chair)
Douglas West	Consultant Thoracic Surgeon (Vice Chair) Bristol (from February 2018 Vice Chair from April 2018)
Shahzeena Aslam	Clinical Oncologist, Cambridge
Elaine Borg	Consultant Histopathologist & Cytopathologist, London
Lynn Campbell	Consultant Medical Oncologist, Belfast
Steve Connor	Consultant Neuro-radiologist (from May 2018) (co-opted expert)
Sujal Desai	Consultant Radiologist, London
Jesme Fox	Medical Director, Liverpool (Lay member)
Clifford Jones	General Practitioner, Gwent
Tom Haswell	Lay member
Sue Maughn	Commissioning Director, London
Andrea McIver	Macmillan Lung Cancer Clinical Nurse Specialist, Liverpool
Neal Navani	Consultant in Respiratory Medicine, London
Marco Scarci	Consultant Thoracic Surgeon, London (until November 2017)
Michael Snee	Consultant Clinical Oncologist, Leeds (until October 2017)
David Waller	Consultant Thoracic Surgeon, London (December 2017 to January 2018
Rhiannon Walters-Davies	Pharmacist, Cardiff
Nigel Westwood	Lay member

1.2 Members of the Guideline Updates Team:

Name	Role
Sohaib Ashraf	Health Economist
Wesley Hubbard	Information Specialist
Thomas Jarratt	Technical Analyst
Ross Maconachie	Technical Adviser (Health Economics)
Toby Mercer	Technical Analyst
Caroline Mulvihill	Technical Adviser
Vonda Murray	Project Manager (from October 2017)
Rebecca Parsons	Project Manager (from October 2017 – November 2017)
Susan Spiers	Associate Director

1.3 Acknowledgements

The development of this guideline was greatly assisted by the following people:

 Technical Support Unit, at University of Bristol, particularly Nicky Welton, and Caitlin Daly for providing the network meta anyalsis on the clinical and cost effectiveness of chemoradiotherapy or surgery with adjuvant treatment for the treatment for N2 stage NSCLC British Thoracic Oncology Group, British Thoracic Society and the the Lung Cancer Clinical Expert Group for participating in the systemic anti-cancer therapies algorithm targeted engagement exercise